ALZAMEND NEURO, INC. Stock-Based Compensation
ALZAMEND NEURO, INC. (ALZN) reported Stock-Based Compensation of $77.20 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-09-10
- ALZAMEND NEURO, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-07-31 was $77.20K, a 79.94% increase year-over-year.
- ALZAMEND NEURO, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-04-30 was $623.81K, a 667.51% increase year-over-year.
- ALZAMEND NEURO, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-01-31 was $9.30K, a 88.56% decline year-over-year.
- ALZAMEND NEURO, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-10-31 was $31.51K, a 61.23% decline year-over-year.
- ALZAMEND NEURO, INC. share-based payment arrangement, noncash expense for fiscal 2026 was $707.53K, a 117.63% increase from fiscal 2025.
- ALZAMEND NEURO, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $325.11K, a 65.98% decline from fiscal 2024.
- ALZAMEND NEURO, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $955.63K, a 73.33% decline from fiscal 2023.
- ALZAMEND NEURO, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $3.58M, a 18.73% decline from fiscal 2022.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-07-31 | $77.20K 10-Q · filed 2026-09-10 | $701.01K derived: sum of 2 quarters · filed 2026-09-10 | $710.31K derived: sum of 3 quarters · filed 2026-09-10 | $741.82K derived: sum of 4 quarters · filed 2026-09-10 |
| 2026-04-30 | $623.81K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-22 | $633.11K derived: sum of 2 quarters · filed 2026-07-22 | $664.63K derived: sum of 3 quarters · filed 2026-07-22 | $707.53K 10-K · filed 2026-07-22 |
| 2026-01-31 | $9.30K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-11 | $40.81K derived: sum of 2 quarters · filed 2026-03-11 | $83.72K 10-Q · filed 2026-03-11 | $164.99K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-10-31 | $31.51K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-09 | $74.42K 10-Q · filed 2025-12-09 | $155.69K derived: sum of 3 quarters · filed 2026-09-10 | $236.97K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-07-31 | $42.90K 10-Q · filed 2026-09-10 | $124.18K derived: sum of 2 quarters · filed 2026-09-10 | $205.46K derived: sum of 3 quarters · filed 2026-09-10 | $286.73K derived: sum of 4 quarters · filed 2026-09-10 |
| 2025-04-30 | $81.28K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-22 | $162.55K derived: sum of 2 quarters · filed 2026-07-22 | $243.83K derived: sum of 3 quarters · filed 2026-07-22 | $325.11K 10-K · filed 2026-07-22 |
| 2025-01-31 | $81.28K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-11 | $162.55K derived: sum of 2 quarters · filed 2026-03-11 | $243.83K 10-Q · filed 2026-03-11 | $325.11K derived: sum of 4 quarters · filed 2026-03-11 |
| 2024-10-31 | $81.28K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-09 | $162.55K 10-Q · filed 2025-12-09 | $243.83K derived: sum of 3 quarters · filed 2025-12-09 | $430.47K derived: sum of 4 quarters · filed 2025-12-09 |
| 2024-07-31 | $81.28K 10-Q · filed 2025-09-10 | $162.55K derived: sum of 2 quarters · filed 2025-09-10 | $349.19K derived: sum of 3 quarters · filed 2025-09-10 | $667.53K derived: sum of 4 quarters · filed 2025-09-10 |
| 2024-04-30 | $81.28K derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-22 | $267.92K derived: sum of 2 quarters · filed 2025-07-22 | $586.25K derived: sum of 3 quarters · filed 2025-07-22 | $955.63K 10-K · filed 2025-07-22 |
| 2024-01-31 | $186.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-03-10 | $504.98K derived: sum of 2 quarters · filed 2025-03-10 | $874.36K 10-Q · filed 2025-03-10 | $1.37M derived: sum of 4 quarters · filed 2025-03-10 |
| 2023-10-31 | $318.34K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-12-11 | $687.72K 10-Q · filed 2024-12-11 | $1.18M derived: sum of 3 quarters · filed 2024-12-11 | $2.69M derived: sum of 4 quarters · filed 2024-12-11 |
| 2023-07-31 | $369.38K 10-Q · filed 2024-09-11 | $860.71K derived: sum of 2 quarters · filed 2024-09-11 | $2.37M derived: sum of 3 quarters · filed 2024-09-11 | $3.08M derived: sum of 4 quarters · filed 2024-09-11 |
| 2023-04-30 | $491.33K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30 | $2.00M derived: sum of 2 quarters · filed 2024-07-30 | $2.72M derived: sum of 3 quarters · filed 2024-07-30 | $3.58M 10-K · filed 2024-07-30 |
| 2023-01-31 | $1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-03-25 | $2.22M derived: sum of 2 quarters · filed 2024-03-25 | $3.09M 10-Q · filed 2024-03-25 | $4.35M derived: sum of 4 quarters · filed 2024-03-25 |
| 2022-10-31 | $715.64K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-12-15 | $1.58M 10-Q · filed 2023-12-15 | $2.84M derived: sum of 3 quarters · filed 2023-12-15 | $3.97M derived: sum of 4 quarters · filed 2023-12-15 |
| 2022-07-31 | $867.34K 10-Q · filed 2023-09-13 | $2.13M derived: sum of 2 quarters · filed 2023-09-13 | $3.26M derived: sum of 3 quarters · filed 2023-09-13 | $4.54M derived: sum of 4 quarters · filed 2023-09-13 |
| 2022-04-30 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-27 | $2.39M derived: sum of 2 quarters · filed 2023-07-27 | $3.67M derived: sum of 3 quarters · filed 2023-07-27 | $4.41M 10-K · filed 2023-07-27 |
| 2022-01-31 | $1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-03-15 | $2.41M derived: sum of 2 quarters · filed 2023-03-15 | $3.15M 10-Q · filed 2023-03-15 | $3.45M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-10-31 | $1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-12-12 | $2.02M 10-Q · filed 2022-12-12 | $2.32M derived: sum of 3 quarters · filed 2022-12-12 | $2.89M derived: sum of 4 quarters · filed 2022-12-12 |
| 2021-07-31 | $739.62K 10-Q · filed 2022-09-13 | $1.04M derived: sum of 2 quarters · filed 2022-09-13 | $1.61M derived: sum of 3 quarters · filed 2022-09-13 | $2.27M derived: sum of 4 quarters · filed 2022-09-13 |
| 2021-04-30 | $296.86K derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-19 | $871.99K derived: sum of 2 quarters · filed 2022-07-19 | $1.53M derived: sum of 3 quarters · filed 2022-07-19 | $2.03M 10-K · filed 2022-07-19 |
| 2021-01-31 | $575.13K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-03-15 | $1.23M derived: sum of 2 quarters · filed 2022-03-15 | $1.74M 10-Q · filed 2022-03-15 | |
| 2020-10-31 | $654.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-12-13 | $1.16M 10-Q · filed 2021-12-13 | ||
| 2020-07-31 | $506.01K 10-Q · filed 2021-09-13 | |||
| 2020-04-30 | $1.80M 10-K · filed 2021-07-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |